6-K filed Apr 2, 2026 at 06:50 ET
Pharvaris reported its 2025 financial results and provided updates on its clinical development pipeline. Key developments include completion of enrollment in the pivotal CHAPTER-3 study for deucrictibant XR with topline data expected in Q3 2026, continued progress on the NDA submission for deucrictibant IR in 1H 2026, and ongoing enrollment in the CREAATE study for AAE-C1INH. The company reported €291.7 million in cash as of December 31, 2025, with full-year R&D expenses increasing to €124.5 million.